Floatz logo

9-valent human papillomavirus recombinant vaccine

Penile/Perineal /Perianal Intraepithelial Neoplasia

Xiamen UniversityvaccinePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Penile/Perineal /Perianal Intraepithelial Neoplasia cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BB
Promitil
Lipomedix Pharmaceuticals Inc.
Phase 1C
Abi-1968
Antiva Biosciences
Phase 1NR

Same molecule, other indications

9-valent human papillomavirus recombinant vaccine is also rated in:

anal canal carcinoma in situDormant
BB
Indicative ·
66 / 100
View asset →
anogenital human papillomavirus infectionDormant
B
Indicative ·
60 / 100
View asset →
penile cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →